Douglas Joshua

5.7k total citations
65 papers, 1.7k citations indexed

About

Douglas Joshua is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Douglas Joshua has authored 65 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 24 papers in Oncology and 23 papers in Immunology. Recurrent topics in Douglas Joshua's work include Multiple Myeloma Research and Treatments (36 papers), T-cell and B-cell Immunology (14 papers) and Immunotherapy and Immune Responses (12 papers). Douglas Joshua is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), T-cell and B-cell Immunology (14 papers) and Immunotherapy and Immune Responses (12 papers). Douglas Joshua collaborates with scholars based in Australia, United States and Spain. Douglas Joshua's co-authors include John Gibson, Ross Brown, P. Joy Ho, Hayley Suen, Joy Ho, Shihong Yang, Christian Bryant, Derek N.J. Hart, Daniel Sze and James Favaloro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Douglas Joshua

64 papers receiving 1.7k citations

Peers

Douglas Joshua
Lene Meldgaard Knudsen Denmark
Sylvia Feyler United Kingdom
Rik Schots Belgium
A. John Ashcroft United Kingdom
Shinichi Mizuno Japan
Thomas Köhnke Germany
Carolina Schinke United States
Witold B. Rybka United States
Carolina Terragna Italy
Felipe de Arriba Spain
Lene Meldgaard Knudsen Denmark
Douglas Joshua
Citations per year, relative to Douglas Joshua Douglas Joshua (= 1×) peers Lene Meldgaard Knudsen

Countries citing papers authored by Douglas Joshua

Since Specialization
Citations

This map shows the geographic impact of Douglas Joshua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Joshua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Joshua more than expected).

Fields of papers citing papers by Douglas Joshua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Joshua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Joshua. The network helps show where Douglas Joshua may publish in the future.

Co-authorship network of co-authors of Douglas Joshua

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Joshua. A scholar is included among the top collaborators of Douglas Joshua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Joshua. Douglas Joshua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Talaulikar, Dipti, Douglas Joshua, John Gibson, et al.. (2022). Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 53(4). 599–609. 1 indexed citations
3.
Joshua, Douglas, Slavica Vučković, James Favaloro, et al.. (2021). Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma. Frontiers in Immunology. 12. 620596–620596. 14 indexed citations
4.
Krishnan, Sabna Rajeev, Gabriele De Rubis, Hayley Suen, et al.. (2020). A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer Journal. 10(3). 37–37. 28 indexed citations
5.
Hocking, Jane S., Anthony P. Schwarer, Robin Gasiorowski, et al.. (2014). Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leukemia & lymphoma. 55(12). 2801–2807. 15 indexed citations
6.
Favaloro, James, Ross Brown, Shihong Yang, et al.. (2014). Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leukemia & lymphoma. 55(12). 2893–2900. 91 indexed citations
7.
Favaloro, James, Ross Brown, Esther Aklilu, et al.. (2013). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Leukemia & lymphoma. 55(5). 1090–1098. 64 indexed citations
8.
Brown, Ross, Hayley Suen, James Favaloro, et al.. (2012). Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. OncoImmunology. 1(9). 1658–1660. 18 indexed citations
9.
10.
Joshua, Douglas, Ross Brown, P. Joy Ho, & John Gibson. (2008). Regulatory T Cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 8(5). 283–286. 33 indexed citations
11.
Osborne, Richard H., et al.. (2007). Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study. Value in Health. 10(6). 451–456. 55 indexed citations
12.
Ling, Silvia, Douglas Joshua, John Gibson, et al.. (2006). Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American Journal of Hematology. 81(2). 110–114. 11 indexed citations
13.
Ho, P. Joy, Lynda J. Campbell, John Gibson, Ross Brown, & Douglas Joshua. (2002). THE BIOLOGY AND CYTOGENETICSOF MULTIPLE MYELOMA. PubMed. 6(3). 276–300. 17 indexed citations
14.
Sharland, Alexandra F., et al.. (1997). Hemodialysis: An appropriate therapy in myeloma-induced renal failure. American Journal of Kidney Diseases. 30(6). 786–792. 11 indexed citations
15.
Brown, Ross, John Gibson, Belinda Pope, et al.. (1996). Nucleoside transporters, bcl‐2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro. European Journal Of Haematology. 56(4). 213–220. 24 indexed citations
16.
Joshua, Douglas. (1996). Myeloma: New aspects of biology, prognosis and treatment. Pathology. 28(1). 2–7. 2 indexed citations
17.
Gibson, John, et al.. (1995). Primary Amyloidosis Co-Presenting with Cervical and Massive Intra-Abdominal Lymphadenopathy. Leukemia & lymphoma. 19(5-6). 519–520. 5 indexed citations
18.
Brown, Ross, et al.. (1991). The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with Myeloma. Leukemia & lymphoma. 5(2-3). 151–155. 18 indexed citations
19.
20.
Joshua, Douglas, et al.. (1987). Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression. British Journal of Haematology. 67(1). 39–44. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lene Meldgaard Knudsen Breakdown of academic impact, for papers by Sylvia Feyler Breakdown of academic impact, for papers by Rik Schots Breakdown of academic impact, for papers by A. John Ashcroft Breakdown of academic impact, for papers by Shinichi Mizuno Breakdown of academic impact, for papers by Thomas Köhnke Breakdown of academic impact, for papers by Carolina Schinke Breakdown of academic impact, for papers by Witold B. Rybka Breakdown of academic impact, for papers by Carolina Terragna Breakdown of academic impact, for papers by Felipe de Arriba
Rankless by CCL
2026